TrialsgrambetaRCTs are beautiful

Haematologic malignancies

BCR-ABL TKIs in CML, BTK and BCL-2 inhibition in CLL, anti-CD38 in myeloma, BCL-2/HMA in AML and CD19 CAR-T in lymphoma.

Trials
4
Years
2003–2019
Sort
  • 2019MAIA⁠Transplant-ineligible NDMMIn 737 patients with newly diagnosed transplant-ineligible multiple myeloma, daratumumab + lenalidomide + dexamethasone improved progression-free and overall survival compared with lenalidomide + dexamethasone.HR 0.56Read →
  • 2018MURANO⁠Relapsed/refractory CLLIn 389 patients with relapsed or refractory chronic lymphocytic leukaemia, fixed-duration venetoclax + rituximab for two years improved progression-free survival compared with bendamustine + rituximab.HR 0.17Read →
  • 2017ZUMA-1⁠Refractory DLBCLIn 101 patients with refractory aggressive large B-cell lymphoma, axicabtagene ciloleucel (anti-CD19 CAR-T) produced durable complete remissions in a setting with no effective standard therapy.Read →
  • 2003IRIS Core⁠Chronic myeloid leukaemiaIn 1,106 patients with newly diagnosed chronic-phase CML, imatinib improved cytogenetic response and progression-free survival compared with interferon-α + cytarabine.76.2% vs 14.5%Read →